Skip to Main Content

A Massachusetts-based synthetic biology company whose research ranges from developing pesticide alternatives for crops to a Covid-19 vaccine candidate plans to go public to advance its RNA manufacturing platform.

GreenLight Biosciences agreed to merge with Environmental Impact Acquisition Corp., a special purpose acquisition company, in a deal that values the firm — which has not yet brought a product to market — at about $1.2 billion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment